NCT00726440 - Are the Continuous Glucose Monitoring Systems Able to Improve Long Term Glycaemic Control in Type 1 Diabetic Patients? | Biotech Hunter

Enrollment

180

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2010

Conditions

Type 1 Diabetes

Interventions

DEVICE

Navigator®

Patients will be encouraged to use the Navigator® all the time and to modify their treatment according to the device measurments. Patients will also follow and educational process in order to adapt insulin doses according to each sensor data

DEVICE

Navigator®

Patients will follow the same educational process as group1 concerning insulin doses adaptation.The duration of the use of the devicewill be determined at the consultation every each 3 months.

DEVICE

Placebo

Patients will have their usual follow up with self-monitoring blood glucose

Trial Locations (19)

4000

CHU Sart Tilman Liège, Liège

13274

CHU Marseille Hôpitaux Sud, Marseille

25030

CHU Jean Minjoz, Besançon

31403

CHU Toulouse, Toulouse

33604

Hopital Haut Leveque, Pessac

34295

Chu Montpellier, Montpellier

35056

CHU Rennes, Rennes

38043

University Hospital Grenoble, Grenoble

42055

Hopital Bellevue, Saint-Etienne

44093

CHU Nantes, Nantes

51100

CHU de Reims-Hôpital Américain, Reims

CHU de Reims-Hôpital Robert debré, Reims

54201

CHU Hôpital Jeanne d'Arc, Nancy

67091

CHU Strasbourg, Strasbourg

69003

Hopital Edouard Herriot, Lyon

75004

Hopital Hotel Dieu, Paris

75013

CHU La Pitié Salpetrière, Paris

75019

CHU Robert Debré, Paris

91100

CH SUD Francilien, Corbeil-Essonnes